|
楼主 |
发表于 2008-11-20 10:56:32
|
显示全部楼层
127-5-第五节 四环素类药物的副作用和毒性
严重影响生命的副作用不常见,低剂量或停药后,轻的副作用是可逆的。在二甲胺四环素控制RA的治疗中,副作用很少见,导致停药的只有7%。; b3 n1 j7 _$ v8 O0 X: T7 w
: o! U( V; B& P 一、对骨、牙生长的影响
/ {+ A( C8 n* t8 Y' z* ~$ q% H! I
四环素可与新形成的骨、牙中所沉积的钙相结合。妊娠5个月以上的妇女服用这类抗生素时,出生的幼儿乳牙可出现荧光、变色、牙釉质发育不全,畸形和生长抑制。幼儿,尤其是出生后第1年,由于肾发育不全,药物不能充分排泄,即使短期用药,也极易引起乳牙的色素沉着和牙釉质发育不全,易于造成龋齿,牙染色由黄转为棕黄。剂量越大,黄染越深,牙釉质发育不全也更加显著。因此,年龄小于7-8岁儿童、怀孕5个月以上和哺乳的妇女等慎用或禁用。
8 C4 F7 K2 r0 _) _! l( T
0 s' V8 z$ ~8 B* y0 \* ^ 二、胃肠道紊乱 ! G: b$ M! M: D$ t8 Q+ Y$ Q$ e+ c
d; N& y- O7 I6 Y 恶心、呕吐、上腹部不适、腹胀、腹泻、舌炎、口腔炎和肛门炎等。减少剂量至50mg,每天1次或2次,或与食物同服,可以减轻症状。在RA病人中,因为 RA本身有关节和全身的症状,同时又用其他有潜在肝脏毒性的药物,因此这些副作用不容易及时发现。为此,要求开始治疗 1个月后每 3个月检查全血细胞计数和肝、肾功能。
* s/ m% `3 i) p* Y$ G* n9 @8 @3 ^
三、头晕或轻度头痛9 K4 S$ g- z& K; ]( Z
j* m+ p. `( v. [ 妇女更加多见。减少开始剂量(50mg,每天1次或2次)可减轻其副作用,在2-4周逐渐增加剂量。: }5 O" m6 q/ M" H! X( S5 J. S
0 H( `6 i1 ?1 n' s% u
四、其他
1 X( X6 p; O5 s8 z" Y. b! h! |, n) j* `5 w: k2 c
有关于服用二甲胺四环素产生光敏反应的报道,服药1年或更长会产生灰黑色素沉着,在身体的任何部位都会有,特别在腿胫部。国外报道二甲胺四环素引起可逆性前庭副作用,包括恶心、呕吐、头晕、眩晕及运动失调。前庭反应妇女较男性多见,发生率与剂量高低无明显关系。脱氧土霉素的皮疹少见。因为四环素降低血浆抗凝活性,所以接受抗凝治疗的病人应该减少抗凝药物的剂量。 1 V' ]0 `% k, B3 J, o% F6 M# X
! c; J6 T* ?$ o
近年来,国外学者在用米诺环素治疗RA的研究过程中,还发现了该药可诱发类狼疮样症状,并称之为“米诺环素诱导自身免疫综合征(minocycline-induced autoimmune syndrome)”,其特点主要有可逆性的关节痛、关节炎、发热、晨僵、皮肤损害,偶有慢性活动性肝炎表现,同时出现抗核抗体阳性及p-ANCA抗体滴度增高。
. c7 B8 z8 e! G1 k" \1 }% x$ r8 _" t; Z1 r
五、菌群失调 2 P6 n" b) N i' o% f8 ?( C
" M# m ~% @% _+ u
长期用四环素后,使正常菌群的分布发生改变,敏感菌受到抑制,耐药细菌、真菌(主要是白色念珠菌)等乘机在体内繁殖,发生消化道、呼吸道和泌尿道等感染。如果发生这种情况,应当马上停药,改用其他药物。脱氧土霉素的肠道二重感染少见。
9 D- A! u! {# b/ w; L2 J; F s$ i$ K1 X& W
综上所述,脱氧土霉素和二甲胺四环素对RA、反应性关节炎、骨关节炎和骨质疏松都有一定的疗效,且有副作用低的优点,尤其适用于肾功能不良的病人,这是一个有潜力的抗风湿药物。
6 b# S& \* E' E9 r6 f0 A3 ^& v ( 叶益新 李小霞 张如峰 )
6 l4 [' W& O2 E- k$ U 参考文献:
" [6 a r/ L9 o0 t. g G' P5 T1 K2 `( Q0 j
杨藻衰.医用药理学.北京:人民卫生出版社,1982.742-749
( N' U& O# L% R' g7 x$ i0 h1 W
9 u+ U( w( O9 `1 U 季颖,张明发.米诺环素治疗类风湿关节炎.中国新药与临床杂志,2000.19(3):220一223 ( W* s6 a" D, e" G' E! x2 C2 i
1 n0 A! l5 a" d; c# o 李小霞,刘恕.美满霉素治疗类风湿关节炎 1例.中华风湿病学杂志,2001.5(4):269 7 i& _; ~2 p# g2 H3 |+ _6 k
' b& J" M8 f% N4 y7 n$ X. l; \$ K 刘子荣,刘丽华,丁长海.米诺环素治疗类风湿关节炎.中国药理学通报,1999.15(6):500 3 \& e! z$ T0 x2 [& b' S+ ]
+ G+ b# q- E. ], D' _# Y' B
领玉胜.二甲胺四环素治疗与类风湿关节炎相关的白细胞碎裂性血管炎.国外医学皮肤性病学分册,1997.23(6):269一370 9 v3 D5 u: Q" p2 h3 X
5 S& B7 _$ b h% q: O
杨俊何.米诺环素治疗类风湿关节炎.国外医学抗生素分册,1996.17(3):233一234 4 @* ?6 T* ^6 p: v/ y! ~/ z& D
2 V- } B) A z' A Cooper SM. Tetracyclines. In: Shaun R, Edward D H. andClement B S, et al. eds,Kelley}s Textbook of Rheumatology. 6thed. Philadelphia: Saunders, 2001. 913一920 1 L7 S) k) t7 o# N
' s" f" \; {0 B% B Alarcon GS. Minocycline for the treatment of rheumatoidarthritis. Rheum Dis Clin North Am,1998.24(3):489一499
+ v, n4 [; w, j
* m1 d5 l& K; D( i. V7 r- c: e# X, Z Alarcon GS. Tetracyclines for the treatment of rheumatoidarthritis. Expert Opin Investig Drugs, 2000.9(7):1491一1498 8 d0 Y9 _9 @6 J( y6 L
1 J- n5 O/ p$ e [* @4 E8 S& f Assad SA,Bernstein EF,Brod B, et al. Extensive pigments-tion secondary to minocycline treatment of rheumatoid arthritis. JRheumatol, 2001.28 (3) :679一682
; g3 O. u* J5 W" v- x: g( G' A! g$ T( Y/ i
Bluhm GB, Sharp JT, Tilley BC, et al. Radiographic results from the minocycline in rheumatoid arthritis(MIRA) trial. JRheum, 1997.24(7)1295一13020 s# G2 b9 F4 ~6 v# m, T8 E
, T( q5 w( F2 c( D$ M) p3 r# {
Case JP. Old and new drugs used in rheumatoid arthritis: ahistorical perspective. Part 2 : the newer drugs and drug strategies.Am J Therapy, 2001.8(3):163一179 * N" _: _) G) C: C6 _! w) U5 R
6 }) k* V8 ~- o8 n2 ?4 W# D
Dodd MA, Dole EJ,Troutman WG, et al. Minocycline-asso-ciated tooth staining. Ann Pharmacotherapy. 1998. 32(9) :887一889 - ?9 Q8 y1 H( D1 r5 P0 L
) y% p& o2 [* I
Elkayam O, Yaron M, Zhukovsky G, et al, Toxicity profileof dual methotrexate combinations with gold, hydroxy-chloroquine,sulphasalazine and minocycline in rheumatoid arthritispatients. Rheumatol Int,1997.17(2) :49一53. {) h) S" f) `" i7 F: O& e7 Q# Y1 s
! U1 L: Q. B* r# Z8 H
Kawanaka N, Yamamura M, Hashimoto H, et al. An evalua-tion of efficacy of minocycline as an anti-rheumatic drug in pa-tients with active and refractory rheumatoid arthritis. Ryumachi.1998.38(6):801一809
$ ]( K! I1 F( ]6 w
& T$ n+ U9 B' u: ^, Y# R Kloppenburg M,Mattie, H,Douwes N, et al. Minocycline inthe treatment of rheumatoid arthritis: relationship of serum con-centrations to efficacy. J Rheum.1995.22(4):611一616
6 {3 C/ w* U r0 _
& N6 E: X: H3 n \+ f Lai NS, Lan JL. Treatment of DMARDs-resistant rheuma-toid arthritis with minocycline: a local experience among the Chi-nese. Rheumatol Int,1998. 17(6) :245一247) J1 O" D$ ^; V6 p
+ H" _; @ K% R; w
Langevitz P, Livneh A, Bank 1, et al. Benefits and risks ofminocycline in rheumatoid arthritis. Drug Saf,2000. 22(5) :405一414' _$ N4 ]2 o/ [4 Y! g6 ^
* t! \6 q! g0 M; X6 W
Marzo-Ortega H, Misbah S, Emery P. Minocycline inducedautoimmune disease in rheumatoid arthritis: a missed diagnosis? JRheumato1,2001.28(2):377一378
7 D: s6 w1 u% x! Q% k) T9 g, P" h9 Q" L& P9 y2 m4 g" \
Nordstrom D, Lindy O, Lauhio A, et al. Anti-collagenolyticmechanism of action of doxycycline treatment in rheumatoidarthritis. Rheumatol Int,1998. 17(5):175一180 2 q x# p: n$ S" p% |/ Z
1 s: u% j( D9 d$ D/ c; ?
O"dell JR,Blakely KW,Mallek JA, et al. Treatment of earlyseropositive rheumatoid arthritis: a two-year, double-blind com-parison of minocycline and hydroxychloroquine. Arthritis Rheum.2001.44(10):2235一2241
1 Z/ t1 s! k* q3 C: L# I( ^! q, R9 \" w7 G! Z6 ^
O'dell JR. How is it best to treat early rheumatoid arthritispatients? Best Pract Res Clin Rheumato1.2001.15(1):125一137
4 B. b* O1 v$ a0 V9 P& Y7 i
2 c' c z0 Q$ L2 C, y/ f/ q( }" p+ k O}dell JR. Is there a role for antibiotics in the treatment ofpatients with rheumatoid arthritis? Drugs. 1999. 57 ( 3 ):279-282
6 M8 u8 T' S' q- y% l! f% d8 g q" o0 k5 s0 T' j: N0 O* N& j0 }3 G7 P* N$ D
O'dell JR, Haire CE, Palmer W, et al. Treatment of earlyrheumatoid arthritis with minocycline or placebo: results of a ran-domized, double-blind, placebo-controlled trial. Arthritis Rheum,1997.40(5):794一796. 4 [' p8 b1 B2 B% f4 l6 ?+ w' b- q' D$ f
O0 B$ _- m% f$ j" Y' @+ \: m
O}dell JR, Paulsen G, Haire CE, et al. Treatment of earlyseropositive rheumatoid arthritis with minocycline: four-year fol-low up of a double-blind, placebo- controlled. Drugs, 1999.57(3):279一282+ j6 x, S* I+ W
6 \, E" x9 [9 ]5 H j7 m
Pillemer SR, Fowler SE, Tilley BC, et al. Meaningful im-provement criteria sets in a rheumatoid arthritis clinkcal trial. MI-RA Trial Group. Minocycline in rheumatoid arthritis. ArthritisRheum.1997.40(3):419一425
3 X% w1 ]7 }" I! ~
8 _5 r7 F% F: ~ B" v9 `, C4 O Pisetsky DS, Clair E W S. Progress in the treatment ofrheumatoid arthritis. JAMA,2001.286(22)2787一2790# T, [* ` M) M% d0 w6 P9 G( i$ l! \& E
- G5 _. t7 U5 |; \7 U0 V6 i, ?8 ?
Skinner M,Cathcart ES, Mills J A, et al. Tetracycline in thetreatment of rheumatoidarthritis a double blind controlled study.Arthritis Rheum. 1971.14(6) :727一732 / }: P: Y6 N4 E; V1 v2 y
! n0 N/ W3 j+ d
Sreekanth VR,Hands R, Wali JP, et al. Doxycycline in thetreatment of rheumatod arthritis--a pilot study. J Assoc PhysiciansIndia,2000.48(8):804一807
% k$ c9 q# h" Z0 i4 n
$ s! K7 v8 l) J G5 P* |& G" { Thomas L. Experimental mycoplasma infections as models ofrheumatoid arthritis. Federation Proc. 1973. 32:143一146
" w- x* W. [. o. ~7 b8 y! W4 o- A4 |; C8 R2 O% X/ [) j" ^
Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline inrheumatoid arthritis. A 48-week, double-blind, placebo-controlledtrial. MIRA Trial Group. Ann Inter Med. 1995.122(2) :81一89
2 }/ V* L G9 T0 c4 s; O! ^- p6 I, [$ T4 G3 R* ?4 z1 ~8 q% c
Tourtellotte CD. Tetracycline in RA. Arthritis Rheum.1971.14(6):788
, s y+ E0 [3 r9 o2 P$ X$ f I& `3 |: ?; h- B6 f
Toussirot E, Despaux J, Wendling D. Do minocycline andother tetracyclines have a place in rheumatology? Rev Rhum EnglEd, 1997.64(7-9):474一480# i: B& h7 o! Z( ~
6 o8 L0 t. R9 D6 E; |
Wasel NR, Schloss EH, Lin AN. Minocycline-induced cuta-neous pigmentation. J Cutane Med Surg. 1998.3(2) :105一1086 o% ]: I; I. F& l
) G0 t: j; b. h% G# [4 I4 e$ l
Westbury LW, Najera A. Minocycline-induced intraoralpharmacogenic pigmentation: case reports and review of the litera-ture. J Periodonto1,1997.68(1):84一91 |
|